Author:
Agada-Amade Yakubu Adole,Ogbuabor Daniel Chukwuemeka,Obikeze Eric,Eboreime Ejemai,Onwujekwe Obinna Emmanuel
Abstract
Abstract
Background
Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared with comprehensive conservative care (CCC) to determine if haemodialysis is socially worthwhile and justifies public funding in Nigeria.
Methods
The study setting is Abuja, Nigeria. The study used a mixed-method design involving primary data collection and analysis of secondary data from previous studies. We adopted an ingredient-based costing approach. The mean costs and benefits of haemodialysis were derived from previous studies. The mean costs and benefits of CCC were obtained from a primary cross-sectional survey. We estimated the benefit-cost ratios (BCR) and net benefits to determine the social value of the two interventions.
Results
The net benefit of haemodialysis (2,251.30) was positive, while that of CCC was negative (-1,197.19). The benefit-cost ratio of haemodialysis was 1.09, while that of CCC was 0.66. The probabilistic and one-way sensitivity analyses results demonstrate that haemodialysis was more cost-beneficial than CCC, and the BCRs of haemodialysis remained above one in most scenarios, unlike CCC’s BCR.
Conclusion
The benefit of haemodialysis outweighs its cost, making it cost-beneficial to society and justifying public funding. However, the National Health Insurance Authority requires additional studies, such as budget impact analysis, to establish the affordability of full coverage of haemodialysis.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Abdi F, Alinia C, Taghizadeh Afshari A, Yusefzadeh H. Cost-benefit analysis of kidney transplant in patients with chronic kidney disease: a case study in Iran. Cost Eff Resour Alloc. 2022;20:37.
2. Himmelfarb J. Haemodialysis: overview. In Oxford Textbook of Clinical Nephrology: Three-Volume Pack 4th edition. Edited by Neil N. Turner and others: Oxford University Press; 2015.
3. Dogo-Muhammad MBW, Sambo A, Uweja H, Mustapha K, Bala A, Sokoto A, Makarfi ZI, Idris M, Musa G, Agada-Amade YA, et al. National Health Insurance Scheme. Abuja, Nigeria: Focal Point; 2012.
4. Agada-Amade YA, Ogbuabor DC, Eboreime E, Onwujekwe OE. Cost analysis of the management of end-stage renal disease patients in Abuja, Nigeria. Cost Eff Resour Alloc. 2023;21:94.
5. Hariparshad S, Bhimma R, Nandlal L, Jembere E, Naicker S, Assounga A. The prevalence of chronic kidney disease in South Africa - limitations of studies comparing prevalence with sub-saharan Africa, Africa, and globally. BMC Nephrol. 2023;24:62.